Hence, in the present study, we evaluated whether the findings of FDG-PET matched the conventional assessments of the DAS28, DAS28-CRP, SDAI and clinical disease activity index (CDAI) at three and six months after initiating TCZ therapy in RA patients. The gene discussed is CRP; the disease is rheumatoid arthritis.